InterventionsHuman trial

Improvements in Cardiometabolic Risk Factors by Body Weight Reduction with Tirzepatide in Adults with Obesity and Prediabetes: A Post Hoc Analysis of the 3-year SURMOUNT-1 study

AHA Scientific Sessions 2025 Abstract

The paper

Luke Joseph Laffin, Naveed A. Sattar, Bruno Linetzky,

Arian W. Plat, Hui Wang, Adam Stefański,

Cleveland Clinic · Eli Lilly (United States)

AHA Scientific Sessions 2025 Abstract · 3 Nov 2025

Presented at AHA Scientific Sessions 2025 · Abstract 4343615

doi.org/10.1161/circ.152.suppl_3.4343615

Survodutide reduces weight in adults with diabetes and obesity
The New England Journal of Medicine · 4 Oct 2026
Retatrutide reduces bodyweight in obesity and type 2 diabetes
Lancet · 4 Oct 2026
A triple-target drug cut body weight by up to 19.7% in a trial
Cell Metabolism · 8 Oct 2026
Retatrutide reduces weight and pain in adults with obesity
The New England Journal of Medicine · 4 Oct 2026